In vitro activity of GAR-936 against Chlamydia pneumoniae and Chlamydia trachomatis

International Journal of Antimicrobial Agents

Volumn 16, Issue 1, 2000, Pages 61-63

  Roblin, Patricia M ^a   Hammerschlag, Margaret R ^a  

^a Dept Pharmacol Stt Univ New Y   (United States)

Author keywords

Chlamydia pneumoniae; Chlamydia trachomatis; GAR 936

Indexed keywords

ANTIBIOTIC AGENT; CLARITHROMYCIN; DOXYCYCLINE; OFLOXACIN; TIGECYCLINE; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; CELL CULTURE; CHLAMYDIA TRACHOMATIS; CHLAMYDOPHILA PNEUMONIAE; CONTROLLED STUDY; HUMAN; HUMAN CELL; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL;

ADULT; ANTI-BACTERIAL AGENTS; CHLAMYDIA INFECTIONS; CHLAMYDIA TRACHOMATIS; CHLAMYDOPHILA INFECTIONS; CHLAMYDOPHILA PNEUMONIAE; HUMANS; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; PNEUMONIA, BACTERIAL;

EID: 0033843634     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(00)00198-9     Document Type: Article

References (9)

1. Block S., Hedrick J., Hammerschlag M.R., Cassell G.H., Craft J.C. Mycoplasma pneumoniae and Chlamydia pneumoniae in community acquired pneumonia in children: comparative safety and efficacy of clarithromycin and erythromycin suspensions. Pediatr. Infect. Dis. J. 14:1995;471-477.
2. Grayston J.T., Campbell L.A., Kuo C.-C., et al. A new respiratory tract pathogen: Chlamydia trachomatis strain TWAR. J. Infect. Dis. 161:1990;618-625.
3. Centers for Disease Control. 1998 Guidelines for the treatment of sexually transmitted diseases. MMWR 1998;47:RR-1.
4. Petersen P.J., Jacobus N.V., Weiss W.J., Sum P.E., Testa R.T. In vitro and in vivo activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936). Antimicrob. Agents Chemother. 43:1999;738-744.
5. Roblin P.M., Montalban G., Hammerschlag M.R. In vitro activities of OPC-17116, a new quinolone; ofloxacin; and sparfloxacin against Chlamydia pneumoniae. Antimicrob. Agents Chemother. 38:1994;1402-1403.
6. Hoellman D.B., Pankuch G.A., Jacobs M.R., Appelbaum P.C. Antipneumococcal activities of GAR-936 (a new glycylcycline), compared to those of nine other agents against penicillin-susceptible and -resistant pneumococci. Antimicrob. Agents Chemother. 44:2000;1085-1088.
7. Kenny GE, Cartwright FD. The susceptibilities of human mycoplasmas to a new glycylcycline, GAR-936. Abstract No. 412, 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 26-29 September, 1999.
8. Hammerschlag M.R., Chirgwin K., Roblin P.M., et al. Persistent infection with Chlamydia pneumoniae following acute respiratory illness. Clin. Infect. Dis. 14:1992;178-182.
9. Muralidharan G, Getsy J, Mayer P, et al. Pharmacokinetics (PK) safety and tolerability of GAR-936, a novel glycylcycline antibiotic, in health subjects. Abstract No. 416, 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 26-29 September, 1999.